Immunohistochemistry Carbonic Anhydrase-9 (CA-9) Test in UAE | 450 AED | 2026 DHA Guidelines

Q1: What is the CA-9 immunohistochemistry test used for in cancer diagnosis?

Answer: The Carbonic Anhydrase-9 (CA-9) immunohistochemistry test is a specialised tissue-based assay that detects a hypoxia-regulated protein predominantly expressed in clear cell Renal Cell Carcinoma (ccRCC), serving as a critical differential diagnostic marker to distinguish ccRCC from other renal tumour subtypes with high specificity. CA-9 overexpression is driven by HIF-1α pathway activation, commonly resulting from VHL gene inactivation, and its membranous staining pattern on IHC provides the surgical pathologist with definitive evidence for classifying a renal mass as ccRCC versus papillary RCC, chromophobe RCC, or oncocytoma — a distinction that directly influences surgical margin planning, targeted therapy selection (including tyrosine kinase inhibitors and mTOR inhibitors), and clinical trial eligibility.

Q2: How should I prepare for the tissue sample collection for this test?

Answer: Tissue sample collection for CA-9 immunohistochemistry requires submission of your tumour specimen as either a Formalin-Fixed Paraffin-Embedded (FFPE) block or fresh biopsy tissue immediately placed in 10% neutral buffered formalin-saline, shipped at controlled room temperature, and must be accompanied by your complete histopathology report, precise biopsy site documentation, and full clinical history to ensure accurate immunohistochemical interpretation by the surgical pathologist. No fasting or dietary restrictions are necessary; however, you must inform your healthcare provider of all anticoagulant or antiplatelet medications you are taking at least five days prior to any planned biopsy procedure.

س3: ماذا تعني نتائج اختبار CA-9 لخطة علاجي؟

Answer: A positive CA-9 immunohistochemistry result — defined as strong, diffuse membranous staining in tumour cells — indicates that your renal tumour is most consistent with the clear cell subtype, which typically carries distinct prognostic implications and guides your oncologist toward evidence-based therapeutic strategies including VEGF-targeted agents, immunotherapies, and appropriate surgical surveillance protocols tailored to your individual tumour stage and grade. A negative CA-9 result does not exclude malignancy; it redirects the diagnostic workup toward alternative renal tumour entities such as papillary or chromophobe subtypes, each requiring fundamentally different management pathways that your multidisciplinary oncology team will discuss with you.